Peripheral neurofibromatosis (NF), first described by Von Recklinghausen in 1882,' is an autosomal dominant disorder with a prevalence of around 30 per 100 000. 2 The major defining features of the disease3 are multiple cafe-au-lait spots, which develop in infancy and early childhood, and multiple cutaneous neurofibromas, usually appearing around the onset of puberty and growing in number and size throughout life. There are a number of well recognised complications of the disease which include skeletal abnormalities (pseudoarthroses and scoliosis), tumours of the central nervous system, and malignant change in the neurofibromas.
The severity of NF is very variable and to many patients it merely presents a cosmetic problem. About 25% of patients,4 however, develop one or more of the severe complications of the disease and their occurrence can not be predicted, even within families.
There is no laboratory test diagnostic for NF and the pathogenesis of the disease is unknown. The identification of a linked genetic marker would thus be a major advance both for prediction and subsequent isolation of the gene itself. 
Material and methods
The families were ascertained through two sources, the records of the Department of Medical Genetics, University Hospital of Wales and the British Neurofibromatosis Patients Association, LINK.
The criteria used for the diagnosis of peripheral neurofibromatosis were as follows.
(1) In adults, six or more cafe-au-lait spots > 1-5 cm diameter and multiple peripheral neurofibromas.
(2) In children, an affected parent and six or more cafe-au-lait spots > 1-5 cm diameter.
All the family members were examined by one of This study was prompted by previous suggestions of linkage between DM and NF from two families in which the two diseases appeared to segregate together. In the family reported by Ichikawa et at8 the origin of DM in generation I is not clear and the evidence that 1.1, who had NF, also suffered from DM is anecdotal. If 1.2 in fact hald DM then there is no evidence of linkage between the two diseases in this family. We consider that this is the more likely situation rather than the possibility that there is more than one genetic locus for NF.
From a clinical viewpoint our results are important but disappointing. Not onlv would a closely linked marker for NF be useful clinically to identify the status of persons at risk, but the mapping of the gene would be a major step toward3s our understanding of the disease and its relationship to other forms of neurofibromatosis. (' A more general analysis of DNA and other genetic markers will now be required to map the NF gene. Samples from the families involved in this study will make an important contribution to this.
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